IP Library Granted Patent US 7,220,780
Granted Patent B2
US 7,220,780 · App. 09/866,961 · Granted May 22, 2007

Naaladase inhibitors for treating retinal disorders and glaucoma

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,220,780
App. No.
09/866,961
Granted
May 22, 2007
Kind
B2
Abstract

The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.

Claims (54)

1. A method for treating retinopathy, age-related macular degeneration or glaucoma comprising administering to a mammal in need of such treatment an effective amount of a compound of formula X

or an enantiomer or a pharmaceutically acceptable equivalent of said compound, wherein:

X 3 is —(CR 36 R 37 ) n SH, —O(CR 36 R 37 ) 2 SH, —S(CR 36 R 37 ) 2 SH or —NR(CR 36 R 37 ) 2 SH;

n is 1-3; and

R, R 36 , R 37 , A 6 , A 7 , A 8 and A 9 are independently hydrogen, C 1 -C 9 alkyl, C 2 -C 9 alkenyl, C 2 -C 9 alkynyl, aryl, heteroaryl, carbocycle, heterocycle, halo, hydroxy, sulfhydryl, nitro, amino, cyano, isocyano, thiocyano, isothiocyano, formamido, thioformamido, sulfo, sulfino, C 1 -C 9 alkylsulfonyl, C 1 -C 9 alkoxy, C 2 -C 9 alkenoxy, phenoxy and benzyloxy, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, heterocycle, alkoxy, alkenoxy, phenoxy and benzyloxy are independently unsubstituted or substituted with one or more substituent(s).

2. The method of claim 1 , wherein the compound of formula X is selected from the group consisting of:

3-(2-mercaptoethyl)-benzoic acid;

3-(mercaptomethyl)-benzoic acid;

2-(mercaptomethyl)-benzoic acid;

5-hydroxy-2-(2-mercaptoethyl)-benzoic acid;

2-(2-mercaptoethyl)-benzoic acid;

5-[(4-carboxyphenyl)methoxy]-2-(2-mercaptoethyl)-benzoic acid;

2-(2-mercaptoethyl)-5-(phenylmethoxy)-benzoic acid;

2-(carboxymethoxy)-6-(2-mercaptoethyl)-benzoic acid;

5-[(3-carboxyphenyl)methoxy]-2-(2-mercaptoethyl)-benzoic acid;

2-(2-mercaptoethyl)-6-(phenylmethoxy)-benzoic acid;

2-[(2-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;

2-[(4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;

3-(2-mercaptoethyl)-[1,1′-biphenyl]-2,3′-dicarboxylic acid;

2-(3,3-dimethylbutoxy)-6-(2-mercaptoethyl)-benzoic acid;

2-(2-mercaptoethyl)-6-(2-phenylethoxy)-benzoic acid;

2-[(2-chlorophenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;

2-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methoxy]-6-(2-mercaptoethyl)-benzoic acid;

2-(2-mercaptoethyl)-6-phenoxy-benzoic acid;

2-(2-mercaptoethyl)-6-phenylamino-benzoic acid;

2-(2-mercaptoethyl)-6-(phenylthio)-benzoic acid;

5′-(1,1-dimethylethyl)-3-(2-mercaptoethyl)-[1,1′-biphenyl]-2,3′-dicarboxylic acid;

3-(2-mercaptoethyl)-[1,1′-biphenyl]-2,4′-dicarboxylic acid;

2-[(4-carboxy-2-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;

2-[(4-carboxy-3-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;

2-[(2-bromo-4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;

2-[(3-bromo-4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;

2-[(4-chlorophenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;

2-(biphenyl-2-ylmethoxy)-6-(2-mercaptoethyl)-benzoic acid;

2-[(3-bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;

2-[(2-bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;

2-(2-mercaptoethyl)-6-[(4-methoxyphenyl)methoxy]-benzoic acid;

2-(2-mercaptoethyl)-6-[(4-methylphenyl)methoxy]-benzoic acid;

2-[(4-bromo-3-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;

2-[(2-carboxy-5-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)-benzoic acid;

5-(mercaptomethyl)-2-(2-phenylethoxy)-benzoic acid;

2-bromo-5-(mercaptomethyl)-benzoic acid;

4-(mercaptomethyl)-[1,1′-biphenyl]-2,3′-dicarboxylic acid;

5-(mercaptomethyl)-2-(phenylmethoxy)-benzoic acid; and

4-bromo-3-(mercaptomethyl)-benzoic acid; and

enantiomers and pharmaceutically acceptable equivalents.

3. The method of claim 1 , wherein the method is for treating retinopathy.

4. The method of claim 3 , wherein the retinopathy is diabetic retinopathy.

5. The method of claim 1 , wherein the method is for treating age-related macular degeneration.

6. The method of claim 1 , wherein the method is for treating glaucoma.

7. The method of claim 2 , wherein the method is for treating retinopathy.

8. The method of claim 7 , wherein the retinopathy is diabetic retinopathy.

9. The method of claim 2 , wherein the method is for treating age-related macular degeneration.

10. The method of claim 2 , wherein the method is for treating glaucoma.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 24, 2009
From: EISAI CORPORATION OF NORTH AMERICA
To: EISAI INC.
Reel/Frame 023699/0188 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2009
From: MGI GP, INC.
To: EISAI CORPORATION OF NORTH AMERICA
Reel/Frame 022277/0779 →
CERTIFICATE OF MERGER OF GRANITE ACQUISITION, INC. WITH AND INTO GUILFORD PHARMACEUTICALS INC. Recorded Dec 23, 2008
From: GRANITE ACQUISITION, INC.; GUILFORD PHARMACEUTICALS INC.
To: MGI GP, INC.
Reel/Frame 022024/0105 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2001
From: SLUSHER, BARBARA S.; WOZNIAK, KRYSTYNA
To: GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION
Reel/Frame 011916/0325 →